Home|Journals|Articles by Year|Audio Abstracts
 

Original Research



The efficacy of Pharmacomechanical catheter-directed thrombolysis in patients with concomitant deep vein thrombosis and pulmonary embolism: A retrospective analysis of 26 patients

Emced Khalil.




Abstract

This study aimed to analyze the impact of pharmacomechanical catheter-directed thrombolysis (PCDT) on venous patency, pulmonary artery systolic pressure, O2 saturation and in-hospital mortality in patients admitted for deep vein thrombosis (DVT) and concomitant pulmonary embolism (PE).
Twenty-six patients presenting with DVT and concomitant non-massive PE were analyzed in aretrospective manner. All subjects underwent PCDT with urokinase. The primary end-point of this study was the difference in pre-and post PCDT sPAP and O2 saturation. Duplex ultrasonography performed before discharge revealed complete recanalization of the compromised vein in 21 (80%) of the subjects. Duplex ultrasonography performed 3 months after discharge showed restenosis of the compromised vein in only two patients (8%). There was partial recanalization in 5 patients (20%). A significant improvement in SaO2 was observed following the infusion of urokinase compared to baseline values (94.5±1.1 % vs. 98.6±0.5 %, p

Key words: Venous thromboembolism, pulmonary embolism, catheter-directed thrombolysis, pulmonary artery pressure






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.